John Byrd
Ohio State University · Cancer and Leukemia Group B
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name John Byrd as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00201721 · Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center · completed · B-Chronic Lymphocytic Leukemia · principal investigator
- Ph1/Ph2NCT00201682 · Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaJohn Byrd · completed · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT00098371 · Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaNational Cancer Institute (NCI) · terminated · B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT00089154 · Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNational Cancer Institute (NCI) · completed · Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT00003620 · Flavopiridol in Treating Patients With Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI) · completed · B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT00058227 · Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaNational Cancer Institute (NCI) · completed · B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma · principal investigator
- Ph1/Ph2NCT00058240 · Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic LymphomaNational Cancer Institute (NCI) · completed · B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT00017472 · Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaNational Cancer Institute (NCI) · completed · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 8 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 03: Leukemia Research (LR)P30CA016058 · NCI · OHIO STATE UNIVERSITY · fiscal years 2005 to 2021 · $52,152 awarded in 2021Grant number is on one of their registry trials
- Targeted Therapies for Richters TransformationR01CA214046 · NCI · OHIO STATE UNIVERSITY · fiscal years 2017 to 2021 · $463,172 awarded in 2021Same name and institution; not confirmed by an ID
- Dual targeting of XPO1 and BTK in B cell malignanciesR01CA192928 · NCI · OHIO STATE UNIVERSITY · fiscal years 2015 to 2019 · $496,655 awarded in 2019Same name and institution; not confirmed by an ID
- OSU K12 Training Grant in OncologyK12CA133250 · NCI · OHIO STATE UNIVERSITY · fiscal years 2008 to 2019 · $809,498 awarded in 2019Same name and institution; not confirmed by an ID
- Molecular Evaluation of Targeted Therapies in Lymphoid MalignanciesR01CA183444 · NCI · OHIO STATE UNIVERSITY · fiscal years 2014 to 2018 · $501,285 awarded in 2018Same name and institution; not confirmed by an ID
- Oncology Training GrantT32CA009338 · NCI · OHIO STATE UNIVERSITY · fiscal years 2017 to 2018 · $544,263 awarded in 2018Same name and institution; not confirmed by an ID
- Novel monocyte effector function in CLL immune therapyR01CA162411 · NCI · OHIO STATE UNIVERSITY · fiscal years 2013 to 2017 · $319,550 awarded in 2017Same name and institution; not confirmed by an ID
- Targeted Therapy for Lymphoid MalignanciesR01CA177292 · NCI · OHIO STATE UNIVERSITY · fiscal years 2013 to 2017 · $536,708 awarded in 2017Same name and institution; not confirmed by an ID
- Innate Immune Therapy for B-Cell MalignanciesP01CA095426 · NCI · OHIO STATE UNIVERSITY · fiscal years 2007 to 2016 · $381,967 awarded in 2016Same name and institution; not confirmed by an ID
- Novel Immunotherapies for Lymphoid MalignanciesR01CA159296 · NCI · OHIO STATE UNIVERSITY · fiscal years 2012 to 2016 · $316,438 awarded in 2016Same name and institution; not confirmed by an ID
- OSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · fiscal years 2014 · $1,455,849 awarded in 2014Same name and institution; not confirmed by an ID
- Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic LeukemiaP50CA140158 · NCI · OHIO STATE UNIVERSITY · fiscal years 2009 to 2013 · $230,527 awarded in 2013Same name and institution; not confirmed by an ID
- Clinical Investigation of Epigenetic TherapyP01CA101956 · NCI · OHIO STATE UNIVERSITY · fiscal years 2006 to 2010 · $501,619 awarded in 2010Same name and institution; not confirmed by an ID
- Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIESR01CA102504 · NCI · OHIO STATE UNIVERSITY · fiscal years 2003 to 2006 · $305,171 awarded in 2006Same name and institution; not confirmed by an ID
- Epigenetic Targeted Therapy for Chronic Lymphocytic Leu*R21CA110496 · NCI · OHIO STATE UNIVERSITY · fiscal years 2004 to 2005 · $306,475 awarded in 2005Same name and institution; not confirmed by an ID
- Molecular Markers: Response to Chemo-immunotherapy in C*R21CA101332 · NCI · OHIO STATE UNIVERSITY · fiscal years 2004 to 2005 · $269,520 awarded in 2005Same name and institution; not confirmed by an ID
- DEPSIPEPTIDE: A NOVEL HISTONE DEACYTLASE INHIBITOR IN LR21CA096323 · NCI · OHIO STATE UNIVERSITY · fiscal years 2002 to 2003 · $328,188 awarded in 2003Same name and institution; not confirmed by an ID
- A PHASE 1 Study of HuD10 IN CLL/SLL PATIENTSR21CA091564 · NCI · OHIO STATE UNIVERSITY · fiscal years 2001 to 2002 · $326,484 awarded in 2002Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT00003620
- Phase I Trials of Anti-Cancer AgentsU01CA076576 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL R GREVER · fiscal years 1998 to 2013
- A Novel Dosing Schedule of Flavopiridol in CLLR21CA112947 · NCI · OHIO STATE UNIVERSITY · PI Thomas S Lin · fiscal years 2005 to 2006Named on NCT00058240
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:49 UTC. The ranking covers the 200 most relevant of 228 PubMed records, and a shared surname and initials can bring in a namesake. All 228 on PubMed
- 2,193 citationsRCR 46.8
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.N Engl J Med · 20131,919 citationsRCR 50.1
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.N Engl J Med · 20141,382 citationsRCR 39.4
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.N Engl J Med · 2018789 citationsRCR 27.0
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.N Engl J Med · 2016763 citationsRCR 23.8
- 744 citationsRCR 14.8
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.Blood · 2013704 citationsRCR 17.9
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.J Clin Oncol · 2021589 citationsRCR 33.6
- Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.Cancer Res · 1998585 citationsRCR 13.0
- 563 citationsRCR 23.2